US OptionsDetailed Quotes

AMGN241011C355000

Watchlist

0.11
0.000.00%

15min DelayTrading Sep 30 13:09 ET

0.00High0.00Low

Amgen Stock Discussion

Kevin Travers

Sep 25 15:25

Columns Wall Street Today | S&P Hits Highs Energy and Semi's Climb, Market Falls

The market fell Wednesday, but Semiconductors and software were climbing again, sending the Nasdaq higher. The S&P hit a new trading record within an hour of trading, but pulled back.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ fell 19 basis points, the $Dow Jones Industrial Average (.DJI.US)$ fell 70, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 4 basis points.
MACRO
Wednesday, Crude Oil Inventories were cut by 4.4M bar...

Tech outperforms after jumbo Fed rate cut: Are bullish signals coming?

Kevin Travers

Sep 25 10:58

Columns Moovin Stonks | Market Falls Wednesday, Vistra and Semi's Are Climbing

Afternoon Traders, happy Wednesday, September 25th. The market was overall falling, but Semiconductors and software were climbing again, sending the Nasdaq higher. The S&P hit a new trading record within an hour of trading, but pulled back.
My name is Kevin Travers; here stonks and stories mooving the U.S. stock market today.
$Amgen (AMGN.US)$ fell 4%, the lowest on the Nasdaq 100 after the firm posted results from two phase th...

Tech outperforms after jumbo Fed rate cut: Are bullish signals coming?

Amusement World

Sep 25 10:15

$Amgen (AMGN.US)$
Will go below 300, can wait

Columns Today's Morning Movers and Top Ratings: SHOP, RIVN, SMCI, DIS and More

Morning Movers
Gapping up
$Shopify (SHOP.US)$ stock soared 17% after the e-commerce platform surpassed quarterly revenue expectations, with its artificial intelligence-powered tools attracting more merchants.
$Disney (DIS.US)$ stock rose by 0.16% in volatile trading as its Entertainment unit, housing Disney+, Hulu, and ESPN+, turning a profit for the first time.
Gapping down
$Super Micro Computer (SMCI.US)$ stock fell 14.2% follo...

nerdbull1669

Aug 6 02:03

Amgen (AMGN) Drug Pipeline and Horizon Integration In Focus

$Amgen (AMGN.US)$ is scheduled to announce Q2 earnings results on 06 August (Tuesday) after the market close.
Amgen (AMGN) reported adjusted EPS of $3.96 in Q1 on revenue of $7.45B that grew 22% Y/Y. The drugmaker had also tweaked its annual outlook at the time, guiding for adjusted EPS of $19 to $20.20 on revenue of $32.5B to $33.8B.
With the expectation of continued positive commentary on MariTide, the company’s injected GLP-1 weight-lo...

Weight-loss drugmakers report strong earnings: Boon or bane?

CHFANTA

Jul 30 10:47

$Amgen (AMGN.US)$ trend seems okay...hmmm wonder how well it close tmr

Meltyy

Jun 17 22:06

$Amgen (AMGN.US)$ 🚨
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO

Meltyy

Jun 7 03:39

🚨 June PDUFAs

» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...

ProperMicheleV

May 29 12:28

Down

I hate these days. I know it's investing & I'm long with my bets, but I have better, more exciting days when I don't see a lot of red. Sucks. And, I was terminated from my job in April & having a hard time getting unemployment. I was a 1099 contractor on that job & the department of labor doesn't know how to process my claim. This is making me low on hard cash & I'm going to have to sell a position or 2, and I DO NOT WANT TO DO THAT, especially with $Esperion Therapeutics (ESPR.US)$. I read...

No comment yet